Literature DB >> 22467511

Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008).

Laurent Peyrin-Biroulet1, Côme Lepage, Valérie Jooste, Jean-Louis Guéant, Jean Faivre, Anne-Marie Bouvier.   

Abstract

BACKGROUND: Few data are available on the incidence, characteristics, treatment, and prognosis of inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) in population-based cohorts.
METHODS: Among the 19,451 new cases of CRC recorded in the Burgundy digestive cancer registry between 1976 and 2008, all cases of IBD-associated CRC were identified. Incidence rates were age-standardized according to the world standard population. Prognosis was determined using univariate and multivariate relative survival.
RESULTS: Thirty-eight IBD-associated CRC were identified (ulcerative colitis, n = 29; Crohn's disease, n = 9). The mean age at CRC diagnosis was greater for patients without IBD than those with IBD (70.9 vs. 56.9 years, respectively; P < 0.001). Distributions of gender, stage at presentation, location, and histological type of CRC did not differ from those of sporadic cases. The overall world age-standardized incidence of IBD-associated CRC per 100,000 was 0.11 (standard deviation [SD]: 0.03) for men and 0.06 (SD: 0.02) for women. Only age was independently associated with IBD-associated CRC (odds ratio [OR]: 0.22; 95% confidence interval [CI]: 0.12-0.43; P < 0.001). Treatment modalities did not differ between IBD and non-IBD patients. Five-year relative survival was 51.9% (95% CI: 51.1-52.8%) in non-IBD patients and 41.3% (95% CI: 24.6-57.2%) in IBD patients (P = 0.201). After adjustment for age, gender, and stage at diagnosis, the excess hazard of death was 1.46 times higher in IBD than in non-IBD patients (95% CI: 0.94-2.27; P = 0.070).
CONCLUSIONS: Apart from age, the characteristics of IBD-associated CRC were similar to those of non-IBD CRC. The prognosis of CRC may be poorer in patients with IBD than in those without IBD.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22467511     DOI: 10.1002/ibd.22935

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  19 in total

1.  The predicting value of postoperative body temperature on long-term survival in patients with rectal cancer.

Authors:  Huichuan Yu; Yanxin Luo; Hui Peng; Liang Kang; Meijin Huang; Shuangling Luo; Wenhao Chen; Zihuan Yang; Jianping Wang
Journal:  Tumour Biol       Date:  2015-05-15

2.  Survival of Colorectal Cancer in Patients With or Without Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Baochi Ou; Jingkun Zhao; Shaopei Guan; Aiguo Lu
Journal:  Dig Dis Sci       Date:  2015-10-30       Impact factor: 3.199

Review 3.  Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer.

Authors:  Marie Muller; Franck Hansmannel; Djesia Arnone; Myriam Choukour; Ndeye Coumba Ndiaye; Tunay Kokten; Rémi Houlgatte; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-04-08       Impact factor: 4.623

Review 4.  Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer.

Authors:  Betty Schwartz; Yitzhak Hadar
Journal:  Ann Transl Med       Date:  2014-02

5.  Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah.

Authors:  N Jewel Samadder; John F Valentine; Stephen Guthery; Harminder Singh; Charles N Bernstein; Yuan Wan; Jathine Wong; Kenneth Boucher; Lisa Pappas; Kerry Rowe; Mary Bronner; Cornelia M Ulrich; Randall W Burt; Karen Curtin; Ken R Smith
Journal:  Dig Dis Sci       Date:  2017-01-03       Impact factor: 3.199

6.  Association between serrated epithelial changes and colorectal dysplasia in inflammatory bowel disease.

Authors:  Alyssa Parian; Joyce Koh; Berkeley N Limketkai; Swathi Eluri; David T Rubin; Steven R Brant; Christina Y Ha; Theodore M Bayless; Francis Giardiello; John Hart; Elizabeth Montgomery; Mark G Lazarev
Journal:  Gastrointest Endosc       Date:  2015-12-18       Impact factor: 9.427

Review 7.  Microscopic features of colorectal neoplasia in inflammatory bowel diseases.

Authors:  Aude Bressenot; Virginie Cahn; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 8.  Colon cancer screening and surveillance in inflammatory bowel disease.

Authors:  Song I Bae; You Sun Kim
Journal:  Clin Endosc       Date:  2014-11-30

Review 9.  A clinical perspective on the role of chronic inflammation in gastrointestinal cancer.

Authors:  Sebastian Rasch; Hana Algül
Journal:  Clin Exp Gastroenterol       Date:  2014-08-11

10.  Conditioned media from macrophages of M1, but not M2 phenotype, inhibit the proliferation of the colon cancer cell lines HT-29 and CACO-2.

Authors:  Alexander Engström; Ann Erlandsson; Dick Delbro; Jonny Wijkander
Journal:  Int J Oncol       Date:  2013-12-02       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.